Beta Drugs a vertically integrated oncology-focused formulations company, has raised primary capital worth Rs 117 crore from HealthQuad Fund II, and other investors including a Singapore-based investment fund and a private wealth management firm for a minority stake in the company.
Beta Drugs offers a broad product portfolio across major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy. Beta Drugs has expanded its footprint to over 46 countries, holding accreditations from regulatory bodies such as ANVISA Brazil, INVIMA, PICS, and EAEU. The company was also honoured with the Forbes “Best Under a Billion” award in 2024.
Credit Source: ExpressPharma
Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.